Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation

NCT00169247 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

156

Enrollment

OTHER

Sponsor class

Conditions

Larynx Cancer
Hypopharynx Cancer

Interventions

DRUG: cetuximab
DRUG: Cisplatin
PROCEDURE: Radiotherapy 70 Gy, 35 fractions

Sponsor

Groupe Oncologie Radiotherapie Tete et Cou

Collaborators

[object Object]